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Abstract 
Escherichia coli has been the organism of choice for the production of different chemicals by 
engineering native and heterologous pathways. In the present study, we simultaneously address 
some of the main issues associated with E. coli as an industrial platform for isoprenoids, including 
an inability to grow on sucrose, a lack of endogenous control over toxic mevalonate (MVA) 
pathway intermediates, and the limited pathway engineering into the chromosome. As a proof of 
concept, we generated an E. coli DH1 strain able to produce the isoprenoid bisabolene from 
sucrose by integrating the cscAKB operon into the chromosome and by expressing a heterologous 
MVA pathway under stress-responsive control. Production levels dropped dramatically relative to 
plasmid-mediated expression when the entire pathway was integrated into the chromosome. In 
order to optimize the chromosomally integrated MVA pathway, we established a CRISPR-Cas9 
system to rapidly and systematically replace promoter sequences. This strategy led to higher 
pathway expression and a 5-fold improvement in bisabolene production. More interestingly, we 
analyzed proteomics data sets to understand and address some of the challenges associated with 
metabolic engineering of the chromosomally integrated pathway. This report shows that 
integrating plasmid-optimized operons into the genome and making them work optimally is not a 
straightforward task and any poor engineering choices on the chromosome may lead to cell death 
rather than just resulting in low titers. Based on these results, we also propose directions for 
chromosomal metabolic engineering. This article is protected by copyright. All rights reserved 
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Introduction 
Bio-based production of fuels and chemicals makes use of cheap, renewable carbon 
sources to synthesize molecules that the traditional chemical industry manufactures from fossil 
resources. Increasing costs and volatility of petroleum prices, in combination with substantial 
improvements in biotechnology, have stimulated the use of microbial production systems for 
fuels and chemicals (Keasling et al., 2012). Advances in synthetic biology in the last two decades 
(Cameron et al., 2014) have enabled the engineering of microbial hosts able to transform 
renewable feedstocks into valuable products ranging from drugs (Ajikumar et al., 2010; Paddon 
et al., 2013) and commodity chemicals (Yim et al., 2011) to biofuels (Atsumi et al., 2008; 
Bokinsky et al., 2011; Dellomonaco et al., 2011; Steen et al., 2010). 
Industrial microbial production of high-volume, low cost chemicals and fuels, however, 
requires very high efficiency in order to compete with the petroleum-based counterparts 
(Meadows et al., 2016). The efficiency of a bioprocess is defined by the microbial host ability to 
transform cheap carbon sources into valuable molecules at high titers, rates and yields. Industry 
is therefore constantly looking for faster ways to engineer these capabilities in order to reduce 
production costs and maximize the profit. The following five host characteristics would be keys 
to bring a microbe closer to industrial application: i) deep understanding of the host metabolism, 
ii) availability of genetic tools, iii) capacity to grow on inexpensive carbon sources with a short 
doubling time, iv) an autonomous, inducer-free expression system that doesn’t allow 
accumulation of toxic metabolites, and v) chromosomally integrated pathway operons to avoid 
genetic instability and the use of expensive antibiotics required to maintain plasmids.  
The two most popular microbial hosts for industrial production are the model eukaryote, 
baker’s yeast (Saccharomyces cerevisiae), and the model prokaryote, Escherichia coli (Westfall 
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and Gardner, 2011), due to the plethora of tools and knowledge available for them. E. coli is 
possibly the most studied organism, and its advantages include: i) rapid doubling time, ii) the 
most diverse set of tools to control gene expression (promoters, expression vectors, etc), iii) ease 
of engineering, iv) fully annotated genome, and v) detailed understanding of its metabolism. All 
these qualities have enabled extensive applications of engineered E. coli for industrial use 
(Keasling, 2010; Yim et al., 2011), and made it the organism of choice by many leaders in the 
biotechnology field (Schirmer et al., 2010; Steen et al., 2010; Westfall and Gardner, 2011). 
However, there are several issues to using E. coli as an industrial host, including i) susceptibility 
to phage contamination (Junker et al., 2006), ii) inefficiency in growing on certain desirable 
carbon sources (especially sucrose), and iii) low recombination capacity of DNA into its 
chromosome (Jeong et al., 2013; Mosberg et al., 2010). The first two issues have been previously 
addressed. Countermeasures for bacteriophage contamination have been developed (Los et al., 
2004; Los et al., 2007), and engineering approaches to introduce effective sucrose utilization 
capabilities are now available even though most industrial strains cannot grow on sucrose (Lee et 
al., 2010; Bruschi et al., 2011). Feedstocks are the most expensive component of a bioprocess 
(Davis et al., 2013; Humbird et al., 2011), and high feedstock cost severely hampers the 
economics of a bioprocess and its competitiveness with petroleum-based chemicals. Sucrose 
from sugarcane is a high purity and low energy input feedstock, and performs as well or better 
than lignocellulosics for greenhouse gas reduction, making it a preferred feedstock for industrial 
fermentation (Renouf et al., 2008; Klein-Marcuschamer et al., 2013). Therefore, engineering 
sucrose utilization is an important feature for an industrial host. 
Extensive research has proven the E. coli DH1 genotype suitable for the production of a 
myriad of isoprenoids as well as fatty acid-derived molecules at high titers (Alonso-Gutierrez et 
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al., 2013, 2015; George et al., 2015; Goh et al., 2014; Steen et al., 2010). Dynamic control of 
expression of the MVA pathway has also been developed in this strain to circumvent endogenous 
control while allowing DH1 cells to sense their own environment and avoid accumulation of 
toxic intermediates (Dahl et al., 2013); this translates into better conversion efficiencies, avoids 
the need for expensive inducers, provides higher isoprenoid yields and improved strain stability – 
all key features for industrial production. DH1 has also been engineered to utilize sucrose albeit 
with some issues such as very slow growth rates and high level of instability (Garcia, 1985; 
Bruschi et al., 2011)). Introduction of the non-PTS (permease) utilization mechanism from E. 
coli W encoded by the csc regulon, overcomes these problems. Key to this success was removal 
of the cscR regulator from the csc regulon and, most critically, introduction in single copy onto the chromosome to avoid severe toxicity and instability which results from plasmid-mediated expression. This approach allows K-12 MG1655, B and C strains to grow at the same 
rate on sucrose as they do on glucose (Bruschi et al., 2011). Engineering sucrose utilization using 
the cscAKB operon would bring DH1 even closer to industrial application. 
In contrast, there is a paucity of publications addressing the metabolic engineering of 
chromosomally integrated production pathways, especially for the MVA pathway in E. coli.    
Although the use of plasmid-based expression systems can achieve high protein levels, this 
presents an inherent segregational and spatial instability and often require the use of expensive 
antibiotics for plasmid maintenance (Friehs, 2004). Therefore, chromosomal integration and 
optimization of heterologous pathways directly in the genome is an important step to generate 
stable and reproducible strains preferred by industry. While yeast has shown highly efficient 
recombination capability to easily integrate large linear pieces of DNA onto specific locations of 
the genome (Szostak et al., 1983), E. coli has a lower capacity to chromosomally integrate large 
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DNA fragments (Jeong et al., 2013; Mosberg et al., 2010; Sawitzke et al., 2007) and this is one 
of the major drawbacks. This probably explains the deficiency in publications addressing 
chromosomal integration of large heterologous pathways, especially in recA- E. coli strains used 
for production (e.g. DH1).   
These considerations demonstrate that the ability to grow on sucrose and the expression 
of the heterologous pathway genes from the host chromosome under the control of self-regulated 
promoters are important features to implement in E. coli for industrial applications. Here, we 
report on approaches to engineer E. coli DH1 as a potential industrial host for the production of 
isoprenoid-based biofuels. We use a transferable cscAKB operon to confer capacity to efficiently 
grow on sucrose (Bruschi et al., 2011), chromosomally integrate the heterologous MVA pathway 
controlled by stress responsive regulation for the production of bisabolene, and develop a new 
engineering approach using CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR) and its associated Cas9 endonuclease) to add/replace T7 promoters (PT7) of 
different strength directly onto the chromosome. Finally, we report the challenges associated 
with this new engineering approach on the chromosome and propose future directions for 
complex pathway optimization in E. coli. 
 
Results 
Generation of an E. coli DH1 strain able to grow and produce bisabolene from sucrose  
To engineer bisabolene production from sucrose as a carbon source, there are two 
options: either express an isoprenoid pathway in naturally occurring sucrose-utilizing E. coli 
strain such as W (Archer et al., 2011) or integrate the sucrose utilization genes into a strain 
previously engineered for the production of isoprenoids, such is DH1. We first explored the 
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former option and transformed plasmids expressing the MVA pathway for the production of 
bisabolene into the natural sucrose utilizer E. coli W. However, the cells grew poorly and did not 
produce bisabolene at detectable levels (data not shown), suggesting there is an intrinsic problem 
with the expression of the MVA pathway genes in this host strain. Thus, we attempted the 
second option and transferred the sucrose utilizing capability from E. coli W into DH1. As 
previously described (Bruschi et al., 2011), the sucrose utilizing operon (cscAKB) from W strain 
was integrated into the DH1 chromosome at the arsB locus using ‘knock-in/knock-out (KIKO)’ 
plasmid vectors (Figure 1), designed to successfully integrate large pieces of DNA into different 
locations of the E. coli chromosome (Sabri et al., 2013). After the cscAKB operon was 
recombined onto the chromosome (under the control of its native constitutive promoter), a new 
strain (DS) was generated. DS and its derivatives were able to grow on sucrose to ODs 
comparable to, or sometimes even higher than those on glucose (Figure 2b).  
DS strain harboring the best combination of plasmids reported for bisabolene production 
(JPUB_002475 + JPUB_002466, Table 1) yielded ~1 g/L of bisabolene using either sucrose or 
glucose (Figure 2a). Under the same conditions, the DH1 strain produced approximately the 
same amount of bisabolene from glucose as DS, but it only showed residual growth and 
production of bisabolene when grown on sucrose (Figure 2a, b), confirming the successfully 
transferred sucrose utilization capability in DS strain. 
Inducer-free, dynamic-controlled production of bisabolene from sucrose 
Strain DS was transformed with plasmid pBbA0c-PgadE-MevT-MBIS (JBEI-2872, Table 
1) that provides MVA pathway enzymes to synthesize farnesyl diphosphate (FPP) under the 
control of FPP-responsive gadE promoter (PgadE) (Dahl et al., 2013). RstA promoter (PrstA) is 
known to be up-regulated in the presence of FPP and used to control the terpene synthase 
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expression that consumes FPP, but its strength was too weak to efficiently express the terpene 
synthase and showed lower terpene production level than the strain with the terpene synthase 
under a stronger promoter (trc promoter, Ptrc) (Dahl et al., 2013). We tried both combinations in 
DS strain using either glucose or sucrose as a carbon source, and surprisingly, the DS strain 
harboring pJBEI-2872 and pRstA-BIS, a complete dynamic system, gave a higher production 
(~850 mg/L; Figure 2c, d) when grown in sucrose over glucose. 
Initial attempts for chromosomal integration of a self-regulated MVA pathway  
We chose the MVA pathway genes for chromosomal integration from the system 
previously shown to have the highest bisabolene yields in E. coli (Alonso-Gutierrez et al., 2015). 
The construct containing all genes in the pathway is over 10Kb and exceeds the optimal size for 
successful λ-red based integration (~2Kb) (Kuhlman and Cox, 2010). Although we successfully 
integrated the sucrose operon (~4Kb) into the E. coli DH1 genome using KIKO vectors, the low 
recombination efficiency in E. coli DH1 (Hanahan, 1983) made this simple integration a difficult 
task even with the aid of well-established recombinases (Datsenko and Wanner, 2000; Jeong et 
al., 2013). We attempted to integrate the entire pathway including the terpene synthase (~12 Kb) 
into the DH1 chromosome using a more efficient methodology based on suicide plasmids that 
would recombine into the genome by a single cross-over (Haldimann and Wanner, 2001; Sabri et 
al., 2013). Nevertheless, we could not get any colonies with the correct integration using this 
method. The large size of the pathway genes and the complexity associated with the pathway 
(Pitera et al., 2007) seem to be the most plausible explanation for these unsuccessful attempts. 
Therefore, we decided to split the pathway into three operons shorter than 5Kb and integrate 
them in three different locations in the genome (Figure 3). With this approach we intended not 
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only to integrate the whole pathway but also to provide a way to achieve the optimal expression 
ratio among the three operons for the best production (Alonso-Gutierrez et al., 2015).  
MVA pathway splitting and integration at different chromosomal locations   
The MVA pathway was split into three operons as previously described (Alonso-
Gutierrez et al., 2015) (Figures 3 and 4). DNA parts were collected from previously published 
BglBrick plasmids (Table 1) and assembled together into KIKO vectors to integrate the operons 
for modules: T (pKIKO-Cm-poxB-PgadE-MevT), M (pKIKO-Kan-lacZ-Ptrc-MevB) and B 
(pKIKO-Kan-rbsAR-LacI-Ptrc-BS-idi-ispA) of the pathway (Figure 1, Table 1). Module T 
includes the MevT operon to transform acetyl-CoA into MVA (Table 1) under the control of the 
FPP-responsive promoter PgadE , which provides dynamic control of pathway expression (Dahl et 
al., 2013). Modules M and B contain codon optimized genes for the optimal expression of 
enzymes transforming MVA into isopentenyl pyrophosphate (IPP) (MevB operon) and IPP into 
bisabolene, respectively, under IPTG-inducible Ptrc promoters (Table 1). Even though PrstA would 
be necessary to provide complete dynamic regulation in combination with PgadE, we anticipated 
that the low transcription rate of PrstA (Dahl et al., 2013) would not be enough to provide the 
necessary enzyme levels of the bisabolene synthase once integrated and therefore we decided to 
use Ptrc. 
From our previous work in engineering the MVA pathway, the ideal relative expression 
ratio among MVA pathway modules was determined as B > M > T (Alonso-Gutierrez et al., 
2015). We used different combinations of plasmid copy number and promoter strength in this 
work, but the chromosomally integrated system does not allow as many levels of expression 
control as plasmid-based system does. It is reported that chromosomal location can markedly 
influence the level of expression of integrated genes (Bryant et al., 2014), which is also observed 
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using KIKO vectors (Sabri et al, 2013), and therefore, we placed the different portions of the 
pathway at distinct locations of the E. coli genome known to have different expression levels to 
achieve this ratio. Three loci (rbsAR, lacZ, and poxB) were selected based on the reports that 
expression levels decreased with distance from the genomic origin of replication (Bryant et al., 
2014; Sabri et al., 2013), and we integrated three modules (B, M and T) at these locations 
respectively. We selected poxB locus to achieve additional benefit of reducing carbon loss by 
acetate formation as previously reported (Goh et al., 2014).  To avoid potential toxicity problems 
by prenyl diphosphate accumulation (Dahl et al., 2013; George et al., 2014), we carefully 
designed the order of integration. Module M was integrated first, considering that the MevB 
operon would not produce any toxic intermediate by itself in the absence of module T (i.e. 
without MVA). We integrated module B next, and finally module T to produce MVA as shown 
in Figure 2.  
After integrating every portion of the pathway, a new strain (named DSTMB or DK1) 
was generated (Table 2, Figure 4). This strain grew to an OD similar to that of the wild-type and 
produced ~77 and ~138 µg/L of bisabolene with glucose and sucrose as carbon source, 
respectively (Figure 6). These titers, however, were significantly lower than those from plasmid-
based system. Therefore, we investigated why such a low production level was achieved from 
the integrated system, and explored novel approaches to optimize the integrated pathway. 
Optimization of chromosomally integrated pathway using CRISPR-Cas9 based approach.  
Plasmid-based pathway expression provides multiple copies of each gene. In contrast, 
when integrated onto the chromosome only one copy of each gene is responsible for the 
expression of the corresponding enzyme required for production. Therefore, the first hypothesis 
to account for the lower production level is that a single copy of pathway gene could not provide 
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sufficiently high enzyme concentrations, and a new strategy to provide higher enzyme 
expression level would be required to address this issue.  
Bacteriophage T7 RNA polymerase (T7RNAP), a highly processive single subunit RNA 
polymerase (RNAP), and its associated promoters (PT7) have been successfully used to achieve 
high expression levels of heterologous enzymes (Koma et al., 2012; Temme et al., 2012b; Wang 
et al., 2012). T7RNAP has a much higher transcriptional capability than the cell’s native RNAP, 
allowing for high expression levels even from a single gene (Studier and Moffatt, 1986), and it 
has been reported that the protein levels achieved from a single chromosomal copy under PT7 can 
be comparable to those achieved from a plasmid-based expression system (Koma et al., 2012). 
Since PT7 is not responsive to the native host RNAP and slight variations in its sequence translate 
into different transcriptional strength, using PT7 provides a completely orthogonal and tunable 
control of expression (Temme et al., 2012a). T7RNAP was transduced into strain DSTMB 
genome between genes ybhB and ybhC generating strain DSTMB7 (or DK4; Table 2; Figure 5). 
Integration was validated both by colony PCR (primer sequences in Supplementary Table S1) 
and by checking the presence of plaques after infection with a T7RNAP dependent phage. Strain 
DK4 was confirmed to contain the csc operon, the whole MVA pathway and a functional 
T7RNAP integrated on the chromosome (Table 2 and Figures 3 and 4). The promoters driving 
the integrated MVA pathway in DK4 were sequentially replaced by PT7 using λ-red mediated 
integration and CRISPR-Cas9 selection of the recombinant strains (Figure 5) with the goal to 
achieve higher transcriptional rates, overall enzyme expression, and ultimately product titers. We 
chose wild type PT7 for modules M and B, which are known to require higher levels of 
expression, while we used “PT7.2_P2” (part number SBa_000445 (Temme et al., 2012)) for the 
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expression of the module T, which is known to require lower expression levels relative to the rest 
of the operons. 
As explained in Figure 4, the CRISPR system used in this work consists of two plasmids 
(pSMR77 and either pMCC or pMCK depending on the resistance marker). pSMR77, which 
provides both the λ-red protein and the Cas9 protein, was first transformed into DK4 to generate 
strain DK15 (Figure 5). By keeping carbenicillin in the medium and the temperature below 
30°C, this plasmid was maintained during iterative rounds of modification. Both pMCC and 
pMCK express the guide RNA to target specific sequences in the E. coli genome to be cut by 
Cas9. gBlock fragments (IDT (Coralville, IA)) coding for the specific crRNAs and surrounded 
by SMR20 (pMCC_fw) and SMR21 (pMCC_rev) were successfully cloned into SmaI-linearized 
pMCC or pMCK vectors using Gibson assembly (Table 1 and Figure 4). The presence of any of 
these vectors alone in combination with pSMR77 would guide the Cas9 to produce double strand 
breaks on two genome sites (protospacers) and therefore guarantee cell death. However, DK15 
cells and their descendants containing pSM77 were co-electroporated with either pMCC or 
pMCK (transcribing the crRNA guiding the Cas9) and the fixing template (gBlock sequence of 
500 bp with upstream and downstream homology of the cutting site) to replace the protospacers 
in the genome with different DNA parts (PT7 promoters in this case). Three fixing templates 
(fixT, fixM and fixB) were used in combination with their respective crRNAs (gCrT-T’, gCrM-
M’, gCrB-B’, Table 1) to remove the protospacers and to integrate a PT7 sequence in its place 
(Figure 4).  At each of these locations, the originally integrated weak promoters (and its 
associated protospacer sequences) were substituted to stronger PT7 responding to T7RNAP 
(Figure 5). 
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To generate strain DK2, DK15 was first transformed with pMCC-gCrB-B’ and a fixing 
template fixB to introduce PT7 in module B. DK2 was subsequently electroporated with pMCK-
gCrM-M’ and fixM to generate DK28, a strain with both modules M and B under PT7 control. 
However, the co-transformation of pMCC-gCrT-T’ and fixT in DK28 did not generate any 
colony with the correct PT7 substitution at the module M. As an alternative, we tried to generate a 
triple substitution first by replacing module T promoter in DK15 using the same combination of 
crRNA and fixing template (pMCK-gCrT-T’ and fixT). This time we got colonies after the 
CRISPR screening and generated strain DK16, in which PT7 drives only module T. This verifies 
that the CRISPR system for module T works and suggests that the previous failure in DK28 
could be related to potential imbalance of protein expression among three operons, which might 
result in the accumulation of toxic intermediates. DK16 was further engineered into strain DK29 
where PT7 drives both modules T and B. However, DK29 was unable to accept the third change 
(a replacement of the Ptrc by a PT7 to drive module M) once again. Finally, we tried the third 
route by substituting Ptrc by PT7 in module M of DK15. DK24 was generated in this way, but 
once again, substitution of module T did not work, reinforcing the hypothesis of pathway 
imbalance.  
 Strain DK16, in which a PT7 drives module T (fixT incorporated to DK4; Table 2, Figure 
4) and its descendent, DK29 (fixB incorporated on DK16 and therefore with PT7 driving both 
modules T and B) experienced increase in bisabolene production compared to its predecessor 
DK4. DK16 produced ~200 µg/L and ~300 µg/L of bisabolene when cultured with glucose and 
sucrose, respectively, representing a ~2.5-fold increase in production compared to DK4, and 
DK29 produced ~435 µg/L of bisabolene using both carbon sources, representing a ~4-fold 
increase compared to DK4 (Figure 6). However, any of the other strains with PT7 driving either 
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module M (DK24), module B (DK2) or both M and B modules (DK28) (Table 2) experienced a 
~2.5-fold decrease in production compared to DK4 (Figure 6). More interestingly, neither the 
combination of T and M modules changes (e.g., fixT+fixM) nor the replacement of all promoters 
could be achieved in any order, and we could not see any colonies from these experiments. 
Rather than a problem with our CRISPR system, this suggests a toxicity issue from unbalanced 
expression of the MVA pathway since every one of these changes could be individually achieved 
in different strain background.  
Proteomics-aided diagnosis and promoter replacement for optimization.  
In this work, to achieve better understanding on the nature of the genomic changes, to 
pinpoint potential bottlenecks, and to inform better engineering strategies, we integrated the 
heterologous pathway directly into the chromosome and modulated pathway expression by 
changing parts such as promoters. Proteomic analysis of the first iteration, with the same 
promoters (Ptrc and PgadE) as the plasmid-based system, revealed that the pathway enzyme level 
from the chromosome was significantly lower (on average, 10-fold lower) than what was 
achieved in the plasmid system (Table 3). To overcome any transcriptional limitation, we 
replaced those promoters with PT7 and the expression levels of the module T enzymes responded 
as expected.  The expression level for the first two enzymes in the operon (AtoB and HMGS) 
dramatically increased in strain DK29, and comparable to the levels of those enzymes achieved 
from plasmid-based systems (Table 3). However, the third gene in the operon (HMGR) showed 
lower expression levels than that in the DK4 strain. More interestingly, the proteomic analysis 
revealed that the fixing template we used to fix module B did not result in a higher level for any 
of the enzymes in the operon but rather a decrease. This could bring some issues on the 
efficiency of the PT7-RBS sequence we used. In addition, module M also showed unexpected 
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behavior. The replacement of the promoter from Ptrc to PT7 did not improve the levels of the first 
two enzymes while the level of PMD (the third and last enzyme of the operon) was increased 
(Table 3). A more systematic approach, beyond the scope of this work, on various components 
such as integration location, promoter selection, RBS selection, and the distance between the 
promoter and RBS will provide better understanding of the protein expression from the 
chromosomal system and enable more accurate design of the system for chromosomal metabolic 
engineering. 
 
Discussion 
In this report, we addressed several approaches to improve E. coli as a host for industrial 
production of isoprenoid-based biofuels. Even though some E. coli strains such as the W strain 
can grow on sucrose (Archer et al., 2011), integration of the MVA pathway was not successful. 
The growth phenotype of the W strain suggests a stress response to the expression of the MVA 
pathway, which might have triggered the host’s natural recombination machinery against the 
pathway on the plasmids, but it still need more evidence to conclude so.  
Although the chromosomal integration was successful at each of the three locations in the 
E. coli DH1 genome, the overall production levels from the integrated strains were significantly 
lower than those from plasmid-based systems. With the rare exception of AtoB, the proteomic 
analysis showed very low protein expression for the integrated pathway genes (only about 10% 
of what is detected from plasmid-based system; Table 3). This is not surprising since there is 
only one copy of each gene in the chromosome while multiple copies are available in plasmid-
based systems. To address this, there was an effort to multiply the copies of the integrated 
pathway genes using antibiotic stress (Tyo et al., 2009). However, the production level was still 
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not comparable to those from the plasmid-based system, and furthermore, the repeated copies of 
antibiotic marker in the chromosome could pose safety concerns associated with the use of 
antibiotic resistance markers in a bioreactor that could be spread by horizontal gene transfer into 
the environment (Hiltunen et al., 2017; Robinson et al., 2016).  
E. coli natively corrects defective protein levels by varying the promoter sequence rather 
than mutating or duplicating coding genes (Amorós-Moya et al., 2010). In this work, we 
attempted to emulate this natural strategy by replacing the promoters in strain DSTMB instead of 
refactoring or adding extra copies of the pathway genes. All the promoters used in strain 
DSTMB for heterologous gene expression respond to E. coli’s native RNAP. However, these 
promoters are rather weak and therefore we had to substitute them with stronger promoters such 
as PT7, in the presence of T7RNAP, and further optimized the integrated pathway by engineering 
regulatory sequences such as promoters and RBSs using CRISPR-Cas9 approach which allows a 
rapid, scar-less and multiplex edition of E. coli genome with high efficiency (Jiang et al., 2013; 
Jiang et al., 2015; Li et al., 2015).  
As described in the results section, we replaced promoters individually at each of the 
three locations with PT7 and improved bisabolene production from sucrose up to 4-fold when 
both modules T and B were overexpressed under PT7. However, the simultaneous replacement of 
all three promoters by PT7 was not successful in any combination. This suggests that there could 
be an intrinsic issue of unbalanced protein expression, which precludes the system from further 
optimization. 
Even though we thoroughly investigated the best relative locations for the integration of 
each of the three operons based on previous literature, the proteomic analysis of the strain 
DSTMB showed that the relative enzyme expression levels were far from the optimal ratio 
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achieved on plasmid-based systems (Alonso-Gutierrez et al., 2015). The rbsAR locus was 
previously reported to allow higher expression levels than lacZ and poxB loci (Sabri et al., 2013), 
and therefore we chose it for the expression of module B of the pathway to achieve the highest 
expression level among three modules (Alonso-Gutierrez et al., 2015). However, the overall 
levels of module B proteins turned out to be the lowest even after we replaced its promoter to PT7 
as shown in Table 3. There are many factors known to influence the level of expression 
including chromosomal location, directionality and genetic context (Block et al., 2012; Bryant et 
al., 2014; Reyes-Lamothe et al., 2012; Sabri et al., 2013), and therefore, using chromosomal 
location by itself might not be enough to control gene expression. Our promoter replacement 
strategy showed some success in engineering gene expression in the chromosome. The 
proteomic analysis revealed that the expression level for the first two enzymes in module T 
substantially increased after the promoter replacement with PT7 (Table 3). However, the 
replacement by PT7 in the modules M and B did not translate as expected even though we have 
confirmed that there were no artifacts in the proteomic analysis and the chromosomal sequence.  
In this work, we originally attempted to optimize a chromosomally integrated MVA 
pathway by aiming to meet a specific ratio of pathway enzymes expression previously shown in 
the plasmid-based systems (Alonso-Gutierrez et al., 2015). Based on our proteomics data, 
however, the results were not consistent to our prediction. We could not clearly explain whether 
this was due to a poor choice of chromosomal location and/or promoter-RBS regulatory parts, 
but we expect a more systematic analysis would be helpful to elucidate these results in the future. 
From the cell growth and the production levels of the genome integrated strains, we 
noticed that the engineering for sub-optimal enzyme levels may cause severe toxicity and cell 
death when performed directly in the genome, while it usually leads only to low-producing 
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phenotypes in plasmid-based strains. The chromosomal pathway optimization strategy based on 
iterative cycles of part replacements and analysis may only be able to cover limited subgroups 
and non-viable intermediate phenotypes could preclude identification of the optimal phenotype. 
Therefore, a technique allowing multiple changes in the chromosome in a concurrent fashion 
would be more desired. It has been reported that CRISPR can edit up to three locations 
simultaneously (Jiang et al., 2015), but many more simultaneous changes might be necessary to 
optimize complex metabolic pathways such as the MVA pathway. Multiplex Automated 
Genome Engineering (MAGE) and its subsequent improved versions (Isaacs et al., 2011; Jeong 
et al., 2013; Wang et al., 2009; Wang et al., 2012) enable the simultaneous change of multiple 
regulatory regions that translate into production improvements. PT7 consists of just 23 bp and 
slight variations in the promoter sequences as well as RBS sequences can provide significantly 
wide range of the transcription strength (Salis et al., 2009; Temme et al., 2012a). However, 
MAGE requires an efficient screening system, and without a proper screening method the use of 
this technique will be limited. Recently, a new method called ‘CRISPR Optimized MAGE 
Recombineering’ (CRMAGE) (Ronda et al., 2016) combines CRISPR as a means of screening 
for strains, and this approach would be a good fit in our chromosomal engineering approach.  
The development of better multiplex editing tools compatible with an automated design-build-
test-learn (DBTL) cycle would be necessary to explore such complex genetic spaces and to 
generate industrially relevant strains. 
Finally, we envision the implementation of a dynamic control system (such as quorum 
sensing (e.g. Lux I/R system) or stress-responsive promoters (e.g. PgadE/PrstA)) to express 
T7RNAP, which would translate into an inducer-free, self-regulating system for chromosomally 
integrated pathways driven by PT7. The resulting strain would work free of expensive antibiotics 
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and inducers while having an improved stability; all of which are key features for an industrially 
relevant host.  
 
Materials and Methods 
All chemicals, solvents and medium components were purchased and used without modification 
from Sigma-Aldrich (St. Louis, MO), Fisher Scientific (Pittsburgh, PA), or VWR (West Chester, 
PA) unless otherwise noted. For targeted proteomics experiments, mass spectrometric-grade 
trypsin was obtained from Sigma-Aldrich and prepared according to manufacturer's instructions. 
DNA synthesis was ordered as gBlocks through IDT (Coralville, IA). DNA concentration was 
estimated using Nanodrop (Thermo, Waltham, MA). 
Strain construction 
E. coli DH10B (Invitrogen, Carlsbad, CA) and pir+ were used as the host for cloning while E. 
coli DH1 (ATCC33849) was used as the host for bisabolene production. All plasmids and strains 
used in this study are described in Tables 1 and 2. MVA pathway genes were taken from the 
previously reported systems (Martin et al., 2003) and include different modifications that 
improved isoprenoid production in plasmid-based systems (Alonso-Gutierrez et al., 2015; Dahl 
et al., 2013). In order to enable rapid cloning and assembly of genes, we employed the BglBrick 
(Anderson et al., 2010) and Gibson (Gibson et al., 2009) cloning strategies. All plasmids denoted 
pBb were prepared using the BglBrick standard collection of expression vectors (Lee et al., 
2011). Cells containing the DE3 lysogen and T7RNAP were constructed by transfection with the 
DE3 lysogen using the λDE3 Lysogenization Kit plus (Novagen, Darmstadt, Germany). The detail 
of strain construction is presented in Supplementary Method. 
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Growth conditions and terpene analysis 
E. coli strains harboring bisabolene production pathways were grown in 8 mL of EZ-Rich 
defined medium (Teknova, Hollister, CA) supplemented with 1% glucose or 1% sucrose and 
appropriate antibiotics in glass culture tubes. Working concentrations were 30, 50 and 100 
μg/mL for chloramphenicol, kanamycin and ampicillin, respectively. Starter cultures were grown 
overnight at 37°C, and all samples were shaken in rotary shakers at 200 rpm (Kühner, Basel, 
Switzerland). Production cultures were inoculated at an optical density (OD600 nm) of 0.1, and 
allowed to continue growth at 30°C, as the lower temperature improved terpene production. Each 
of the different strains was induced at OD600nm ~0.4 with 500 μM of isopropyl β-d-1-
thiogalactopyranoside (IPTG) concentrations. Samples for both terpene production and OD600 nm 
production were taken at 24 and 48 hours while proteomic measurements were only performed at 
24 h during late exponential phase. For production assays, a dodecane layer (10% by volume) 
was added to the culture upon induction to trap the terpene, and 10-100 μL of the organic phase 
was sampled and diluted 2- to 100-fold (depending on the final concentration in the culture) to be 
analyzed using gas-chromatography mass-spectrometry (GC/MS) as reported previously 
(Alonso-Gutierrez et al., 2013). 
λ-Red mediated chromosomal integration of the MVA pathway 
Since the pathway is much bigger (~15Kb) than the recommended DNA size for λ-Red mediated 
integration (~2Kb (Kuhlman and Cox, 2010)), we divided the pathway into three operons with 
the size of 4-5Kb and PCR-amplified them as cassettes surrounded by 500bp homology arms 
using KIKO vectors as templates to be independently integrated at three different locations in the 
DH1 genome (Sabri et al., 2013). The detail of chromosomal integration procedure is presented 
in Supplementary Method. 
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CRISPR-Cas9 selection protocol 
We used CRISPR-Cas9 to individually substitute the promoter driving each of the three MVA 
pathway modules (i.e. T, M, and B) in the DSTMB7 (or DK4) with PT7. The detail of CRISPR-
Cas9 selection protocol is presented in Supplementary Method. 
Targeted proteomics 
Targeted proteomics was performed as previously described (Alonso-Gutierrez et al., 2015), and 
detailed method is presented in Supplementary Method. 
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Tables caption 
Table 1. Description of E. coli base strains, plasmids and gene operons used in this study. 
 
Table 2. Nomenclature of engineered DH1 strains containing editions of the integrated MVA 
pathway. fixB(g44) is a fixing template to substitute Ptrc by PT7 in front of AgBIS at rbsR 
location. fixT(g47) is a fixing template to substitute PgadE by PT7 in front of MevT at poxB 
location. fixM(g48) is a fixing template that substitute Ptrc by PT7 promoter in front of MBI at 
lacZ location. 
 
Table 3. Relative protein levels (chromatogram peak area) from the chromosomally integrated 
MVA pathway in strain DK4 and its different levels of optimization (Figure 6) after 24 hours of 
growth. Green and red colored cells represent protein peak areas that had been up or down-
regulated, respectively, compared to the original DK4 strain. Results are the average of three 
biological replicates (error bars are within 1-15% of the value and not shown for clarity). 
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Figures captions 
Figure 1. Cloning methodology of pathways of interest from BglBrick vectors into KIKO 
vectors for chromosomal integration. POI: Promoter of interest; GOI: Gene(s) of interest; MCS: 
multiple cloning site; HL: Hairpin loop; HA: Homology arm; FRT: Flippase recombinase target 
sites; KanR, CmR and AmpR: kanamycin, chloramphenicol and ampicillin resistance gene. 
 
Figure 2. Production of bisabolene and growth curves from different strains grown for 96 hours 
under the same conditions using either 1% of glucose (solid lines and bars) or 1% of sucrose 
(dashed lines and bars) as the carbon source. a) Bisabolene titers and b) OD600nm was measured at 
24, 48 and 96h (left to right stacked bars) and compared between E. coli DH1 (wild type; dotted 
bars) versus DS strain (DH1wt with cscAKB operon integrated in the chromosome; white bars) 
either grown in glucose (solid lines) or sucrose (dashed lines). Both strains were transformed 
with plasmids pBbA5c-MevT(co)-T61-MBIS-T21-Ptrc-AgBIS (JPUB_002475) and pTrc-AgBIS 
(JPUB_002466). c) Bisabolene titers and d) OD600nm was measured at 24, 48 and 96h (left to 
right stacked bars) and compared between E. coli DS strains transformed with plasmid pBbA0c-
PgadE-MevT-MBIS (JBx_000909) and either pTrc-AgBIS (JPUB_002466; grey lines) or pPrstA-
AgBIS (JBx_001052; black lines). Strains were grown either in glucose (solid lines) or sucrose 
(dashed lines). Results are the average of three or more biological replicates. 
 
Figure 3. Integration strategy of the mevalonate pathway (MVA) (for production of bisabolene), 
the cscAKB operon (for sucrose ultilization) and the DE3 prophage (for T7RNAP expression) 
into the E. coli chromosome; 1st) Module M was integrated at the lacZ locus; 2nd) The sucrose 
utilization operon was integrated at the arsB locus; 3rd) Module B was integrated at the rbsAR 
locus close to the origin of chromosomal replication (oriC) and therefore with likely higher 
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transcription activity. 4th) The top portion of the MVA pathway (module T) was integrated at 
poxB. Finally, the T7 RNA polymerase (T7RNAP) gene was transduced into the chromosome as 
part of the DE3 lysogen. Since E. coli is not able to produce MVA, the integration of module T 
as the last step avoids potential toxicity problems of intermediates that would otherwise 
accumulate in the absence of a complete MVA pathway. All integrations (except for the 
T7RNAP that was mediated by phage transduction) were done by homologous recombination 
between ~500 bp homology arms (“_up” and “_dw”) surrounding each cassette and the 
chromosome. Recombinants were screened using different antibiotic markers that were 
subsequently removed using flippase recognition target (FRT) sites surrounding each marker to 
loop it out and enable reuse of the marker in subsequent engineering steps. The number of base 
pair next to each target loci, indicates its chromosomal location relative to the threonine (thr) 
locus. 
 
Figure 4. Chromosomally integrated pathway optimization via CRISPR-Cas9. a) A two-plasmid 
system was used. pSMR77 codes for λ-Red expression under arabinose-inducible PBAD promoter 
and the Cas9 enzyme under a native constitutive promoter from Streptococcus pyogenes. 
Plasmid pMCC or pMCK (with either chloramphenicol or kanamycin antibiotic marker, 
respectively) expresses crRNA (CRISPR RNA) under the native constitutive promoter from S. 
pyogenes. b) This crRNA guides the Cas9 protein to two regions of chromosomal DNA (# and 
#’). New targets can be changed by a two-piece Gibson assembly between a linearized pMCC/K 
plasmid using SmaI and a gBlock fragment providing the crRNA and the promoter sequence. 
Co-selection of pSMR77 and either pMCC or pMCK leads to cell death unless a “fixing 
template” (double stranded DNA with homology to chromosomal DNA) is provided to replace 
the target sequences in the chromosome (protospacers)). c) Two protospacer target sites 
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surrounding each of the promoters controlling expression of module T (CrT/T’), module M 
(CrM/M’) and module B (CrB/B’) were selected to screen against cells which did not recombine 
the PT7 (fixing templates fixT, fixM and fixB respectively). AcCoa; acetyl-CoA; MVA: 
mevalonate; IPP: isopentenyl pyrophosphate; BIS: bisabolene. 
 
Figure 5. Strain nomenclature, characteristics and genealogy. Starting from a wild type strain of 
E. coli DH1 (DH1wt) a new strain called DSTMB7 was generated. DSTMB7 (also known as 
DK4) contains into the chromosome: i) the cscAKB operon to grow on sucrose (S, open triangle), 
ii) the MVA pathway operons (i.e. MevB (M), AgBIS-idi-ispA (B) and MevT (T)) to produce 
bisabolene from acetyl-CoA, and iii) the DE3 prophage to express T7RNAP. The different parts 
were sequentially integrated into its chromosome using different strategies: 1st) both the MVA 
pathway and the sucrose operons were first cloned from BglBrick parts into KIKO vectors 
(Figure 1), PCR amplified and chromosomally integrated using classic λ-Red recombination and 
antibiotic marker selection (left box). 2nd) the λ(DE3) prophage was integrated via transduction 
providing expression of T7RNAP under the control of Plac (middle box). 3rd) Finally, MVA 
pathway optimization was achieved directly from the chromosome of DSTMB7 by replacing 
original promoters (small bended arrows) for PT7 (big bended arrows) using CRIPSR-Cas9 
selection (right box).  
 
Figure 6. Bisabolene production from chromosomally integrated MVA pathway strains with 
different level of optimization after 48 hours of growth. Red dashed line indicates the basal 
production level of strain DK4 before any promoter replacement via CRISPR was performed. 
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Figure 4   
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Figure 5   
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Figure 6 
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Table 1. Description of E. coli base strains, plasmids and gene operons used in this study. 
E. coli strain Description  Reference(s) 
DH1 E. coli K-12; F- endA1 recA1 gyrA96 thi-1 glnV44 relA1 hsdR17(rK- mK+) λ- (Hanahan, 1983) 
DH10B F- endA1 recA1 galE15 galK16 nupG rpsL ΔlacX74 Φ80lacZΔM15 araD139 Δ(ara,leu)7697 mcrA Δ(mrr-hsdRMS-mcrBC) λ- (Casdaban & Cohen, 1980) 
S-17 λpir+ TpR SmR recA thi pro hsdR-M+RP4: 2-Tc:Mu: Km Tn7 λpir (Edwards et al., 2011) 
PIR1 F- ∆lac169 rpoS(Am) robA1 creC510 hsdR514 endA recA1 uidA(∆MluI)::pir-116  
 
Invitrogen 
Plasmid reference Plasmid name Description  
(Origin of replication, Antibiotic marker, Promotors and Operons) 
Reference(s) 
JPUB_002475 pBbA5c-MevT(co)a-T61b -MBISc-T21d-Ptrc-AgBISe p15A, Cmr, PlacUV5, MevT(co), T1, MBIS, T1002, Ptrc, AgBS (Alonso-Gutierrez et al., 2015) 
JBx_000909 pBbA0c-PgadE-MevT-MBISf p15A, Cmr, PgadE, MevT, MBIS (Dahl et al., 2013) 
JBx_013443 pBbA0c-PgadE-MevT p15A, Cmr, PgadE, MevT (Dahl et al., 2013) 
JPUB_002466 pTrc-AgBIS colE1, Ampr, Ptrc, AgBIS  (Alonso-Gutierrez et al., 2015) 
JBx_014141 pBbE1a-T1002-Trc colE1, Ampr, Ptrc, Terminator T1002 (This work) 
JBx_001334 pBbB1k-MevB(CO) pBBR1, Kanr, MevBi (This work) 
JBx_001052 pRstA-AgBIS colE1, Ampr, Ptrc, AgBIS (This work) 
JBx_074937 pKIKO-Kan-lacZ-Ptrc-MevB R6K, Kanr, lacZ gene homology, Ptrc, MevB (This work) 
JBx_026115 pKIKO-Cm-arsB-cscAKB R6K, Cmr, arsB gene homology, Pconst, cscAKB for sucrose uptake (This work) 
JBx_074936 pKIKO-Kan-rbsAR-LacI-Ptrc-BIS-idi-ispA R6K, Kanr, rbsAR gene homology, Ptrc, AgBIS, idi, ispA (This work) 
JBx_088101 pKIKO-Cm-poxB-PgadE-MevT R6K, Cmr, poxB gene homology, PgadE, MevT (This work) 
JBEI-2706 pKD46 OriR101/repA101ts, Ampr, Pbad, λ Red (γ, β, exo) (Datsenko and Wanner, 2000) 
JBx_026997 pCP20 OriR101/repA101ts, Ampr, FLP recombinase (Cherepanov and Wackernagel, 1995) 
JBEI-9382 pKD46-Cas9 (pSMR00077) OriR101/repA101ts, Ampr, Pbad, λ Red (γ, β, exo), PSpyog, Cas9, tracrj (This work) 
JBEI-9390 pMCC  p15A, CasE1, Cmr, (This work) 
 
 
  
 A
cc
ep
te
d
 P
re
p
ri
n
t
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
JBEI-10488 pMCK  p15A, CasE1, Kanr, (This work) 
JBx_063298 pMCC-gCrB-B’ k p15A, CasE1, Cmr, PSpyog-Rk-SpacerB-Rk-SpacerB’-Rl (This work) 
JBx_063300 pMCK-gCrT-T’ k p15A, CasE1, Kanr, PSpyog-Rk-SpacerT-Rk-SpacerT’-Rl (This work) 
JBx_063300 pMCC-gCrT-T’ k p15A, CasE1, Cmr, PSpyog-Rk-SpacerT-Rk-SpacerT’-Rl (This work) 
JBx_063302 pMCK-gCrM-M’ k p15A, CasE1, Kanr, PSpyog-Rk-SpacerM-Rk-SpacerM’-Rl (This work) 
JBx_074941 pMCC-gCrM-M’ k p15A, CasE1, Cmr, PSpyog-Rk-SpacerM-Rk-SpacerM’-Rl (This work) 
 
a MevT(co): contains genes for the conversion of acetyl CoA to mevalonate: acetoacetyl-CoA synthase from E. coli (AtoB), HMG-CoA synthase from Saccharomyces cerevisiae (HMGS), and 
HMG-CoA reductase from Saccharomyces cervisiae (HMGR) (Tsuruta et al., 2009) codon optimized for E. coli  
b T61: T1006 terminator followed by Ptrc 
c MBIS: contains genes for the conversion of mevalonate to isoprenoid precursors (IPP and DMAPP): mevalonate kinase (MK), phosphomevalonate kinase (PMK), mevalonate diphosphate 
decarboxylase from S. cerevisiae (PMD) and isopentenyl diphosphate isomerase (idi) and farnesyl diphosphate synthase (ispA) from E. coli (idi) (Martin et al., 2003). These genes have been fixed 
for expression in E. coli as previously described (Redding-Johanson et al., 2011) 
d T21: T1002 terminator followed by Ptrc 
e AgBIS: Bisabolene synthase coding sequence from Abies grandis codon-optimized for E. coli 
f Plasmid that expresses all genes necessary to transform AcCoA into IPP/DMAPP, which contains atoB, idi and ispA from E. coli and HMGS, HMGR, MK, PMK and PMD from S. cerevisiae in 
its original form (i.e non codon-optimized), under the control of a stress-responsive dynamic promoter (PgadE) as previously described (Dahl et al., 2013) 
g MTSA operon contains genes for the conversion of acetyl CoA to mevalonate: acetoacetyl-CoA synthase from E. coli (atoB), HMG-CoA synthase (HMGS) and HMG-CoA reductase (HMGR) 
from Staphylococcus aureus (Baliobar et al., 2009) codon optimized for E. coli. 
h T1: double terminator followed by Ptrc promoter 
i MevB: MevB operon contains genes for the conversion of mevalonate to isoprenoid precursor (IPP): MK, PMK, PMD from S. cerevisiae (Martin et al., 2003). These genes have been codon 
optimized for expression in E. coli as previously described (Redding-Johanson et al., 2011) 
jtrans-activating crRNA (TRACR) 
kgCr stands for ‘gBlock transcribing crRNA’ and B-B’, M-M’ and T-T’ stand for pairs of spacers surrounding the promoter driving modules B, M or T, respectively 
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lClustered interspaced Repeat from Streptococcus pyogenes (Spyog) 
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Table 2. Nomenclature of engineered DH1 strains containing editions of the integrated MVA pathway. fixB(g44) is a fixing template 
to substitute Ptrc by PT7 in front of AgBIS at rbsR location. fixT(g47) is a fixing template to substitute PgadE by PT7 in front of MevT at 
poxB location. fixM(g48) is a fixing template that substitute Ptrc by PT7 promoter in front of MBI at lacZ location. 
Acronym Description Synonym Reference 
DH1 E. coli K-12; F-, λ-, endA1, recA1, gyrA96, thi-1, glnV44, relA1, hsdR17(rK- mK+) D Hanahan, 1983 
DS DH1 arsB::cscAKB DS This Study 
DS7 DS λ(DE3) DS7 This Study 
DM DH1 lacZ::Ptrc-MevB DM This Study 
DSM DS lacZ::Ptrc-MevB DSM This Study 
DSMB DSM rbsR::Ptrc-BIS-idi-ispA DSMB This Study 
DSTMB DSMB poxB::PgadE-MevT DK1 This Study 
DSTMB7 DSMB poxB::PgadE-MevT, λ(DE3) DK4 This Study 
DSTMB7_fixB DSMBT7; rbsR::PT7-BIS-idi-ispA DK2 This Study 
DSTMB7_fixT DSMBT7; poxB::PT7-MevT DK16 This Study 
DSTMB7_fixM DSMBT7; lacZ::PT7-MevB DK24 This Study 
DSTMB7_fixB_fixT DSMBT7; rbsR::PT7-BS-idi-ispA, poxB::PT7-MevT DK29 This Study 
DSTMB7_fixB_fixM DSMBT7; rbsR::PT7-BS-idi-ispA, lacZ::PT7-MevB DK28 This Study 
DSTMB7_fixT_fixM DSMBT7; poxB::PT7-MevT, lacZ::P T7-MevB No colonies This Study 
DSTMB7_fixB_fixM_fixT DSMBT7; poxB::P T7-MevT, lacZ::P T7-MevB, rbsR::P T7-BS-ispA No colonies This Study 
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Table 3. Relative protein levels (chromatogram peak area) from the chromosomally integrated MVA pathway in strain DK4 and its 
different levels of optimization (Figure 6) after 24 hours of growth. Green and red colored cells represent protein peak areas that had 
been up or down-regulated, respectively, compared to the original DK4 strain. Results are the average of three biological replicates 
(error bars are within 1-15% of the value and not shown for clarity).  
 
   Module 1 Module 2 Module 3  
 Carbon source Strain AtoB HMGS HMGR MK PMK PMD IDI ISPA BIS  
 
SUCROSE 
Plasmid Control 1877 18423 3784 34693 20883 74977 195998 69861 84941  
 DK4 3309 1714 383 3345 3064 12667 763 11945 1409  
 DK2 1789 1205 209 3216 2855 13038 788 11111 356  
 DK28 1264 724 188 1299 3932 54611 619 13023 444  
 DK24 884 529 302 531 1273 18411 734 8993 1004  
 DK16 4922 4447 40 1525 890 5518 499 6580 636  
 DK29 12701 11639 382 2953 2389 10626 912 11446 2503  
             
 
GLUCOSE 
Plasmid Control 1229 13363 3766 22691 38889 149373 215637 64590 138784  
 DK4 1027 698 375 3177 3445 11064 998 15079 1449  
 DK2 1120 769 416 3996 4416 14183 1111 17492 296  
 DK28 1441 984 156 1531 5335 55231 1007 18000 1208  
 DK24 502 413 408 555 2276 18571 2226 10981 1979  
 DK16 3983 3655 208 1171 789 4526 219 6859 539  
 DK29 6288 6841 349 1872 746 5529 547 8696 2526  
             
